EMA seeks executive director

Andreas Pott will be acting executive director until position is filled

The European Medicines Agency (EMA) is seeking a new executive director. Its current head, Thomas Lönngren, is leaving the post on 31 December, following the end of his second five-year mandate.

While EMA searches for a permanent replacement, its current head of administration, Andreas Pott, will serve as acting executive director.

University of Hamburg graduate, Pott has been the agency’s administration chief since 2000, having previously worked for the European Parliament and the EU’s translation service.

Swede Lönngren is a former deputy director-general of the Swedish Medical Products Agency (MPA).

You may also like

Manufacturing

Pharmaceutical labelling in focus at Interpack 2026

Well prepared for new requirements. The upcoming reform of EU pharmaceutical legislation is expected to bring stricter requirements for traceability and labelling. The new 152E HC wrap-around labelling machine, developed specifically for contract packers, covers a wide product range with minimal change parts. Also on display: specialised labelling machines for automated product handling of small batches and high-speed labelling applications.
Cell & Gene Therapy

First CAR-T therapy for solid tumours set to launch in China

Claudin18.2-targeting CAR-T therapy satri-cel (CT041) is expected to become the first treatment of its kind for solid tumours, offering a new option for patients with advanced gastrointestinal cancers
Manufacturing

Virica Biotech and FUJIFILM Biosciences collaborate to boost AAV vector yields in HEK293 manufacturing system

Virica Biotech has announced a collaboration with FUJIFILM Biosciences to co-develop an off-the-shelf enhancer-media solution combining Virica's VSE technology with FUJIFILM's BalanCD HEK293 system, targeting improved AAV productivity and process robustness for gene therapy manufacturers
Marketing

Ofichem consolidates six brands into single integrated CDMO and pharmaceutical supplier identity

Dutch family-owned pharmaceutical company Ofichem has unified its six business units — spanning API, drug substance, drug product and distribution — under a single trading name
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Accelerating the development of bispecific antibodies

Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
Analysis

Conjugation chemistry key to unlocking next-generation oligonucleotide therapies, says Bachem

As demand for oligonucleotide therapeutics accelerates, Bachem's Director of Oligonucleotide Production explains how conjugation chemistry is helping CDMOs overcome delivery challenges
Manufacturing

UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Subscribe now